Genetics and Hypertension: Is It Time to Change My Practice?

Canadian Journal of Cardiology

Volumn 28, Issue 3, 2012, Pages 296-304

  Delles, Christian ^a   Padmanabhan, Sandosh ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 17; CYTOCHROME P450 1A2; FIBROBLAST GROWTH FACTOR 5; PROTEIN SH2; TAMM HORSFALL GLYCOPROTEIN; VOLTAGE GATED CALCIUM CHANNEL;

BLOOD PRESSURE; BLOOD PRESSURE REGULATION; CARDIOVASCULAR RISK; CLINICAL PRACTICE; GENE LOCUS; GENE MAPPING; GENE SEQUENCE; GENETIC ASSOCIATION; GENETIC HETEROGENEITY; GENETIC LINKAGE; GENETIC VARIABILITY; GENETICS; GENOTYPE; GENOTYPE ENVIRONMENT INTERACTION; HUMAN; HYPERTENSION; MEDICAL DECISION MAKING; MOLECULAR PATHOLOGY; PATHOPHYSIOLOGY; PHARMACOGENETICS; PHENOTYPE; REVIEW; RISK ASSESSMENT; SINGLE NUCLEOTIDE POLYMORPHISM;

ANTIHYPERTENSIVE AGENTS; FEMALE; FORECASTING; GENETIC ASSOCIATION STUDIES; GENETIC PREDISPOSITION TO DISEASE; GENOME-WIDE ASSOCIATION STUDY; HUMANS; HYPERTENSION; MALE; MOLECULAR TARGETED THERAPY; PHARMACOGENETICS; PHENOTYPE; PHYSICIAN'S PRACTICE PATTERNS; RISK ASSESSMENT; TREATMENT OUTCOME;

EID: 84860920071     PISSN: 0828282X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cjca.2012.02.004     Document Type: Review

References (78)

1. Lewington S., Clarke R., Qizilbash N., Peto R., Collins R. Age-specific relevance of usual BP to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002, 360:1903-1913.
2. Kearney P.M., Whelton M., Reynolds K., et al. Global burden of hypertension: analysis of worldwide data. Lancet 2005, 365:217-223.
3. Perkovic V., Huxley R., Wu Y., Prabhakaran D., MacMahon S. The burden of blood pressure-related disease: a neglected priority for global health. Hypertension 2007, 50:991-997.
4. Feinleib M., Garrison R.J., Fabsitz R., et al. The NHLBI twin study of cardiovascular disease risk factors: methodology and summary of results. Am J Epidemiol 1977, 106:284-285.
5. Mongeau J.G., Biron P., Sing C.F. The influence of genetics and household environment upon the variability of normal blood pressure: the Montreal Adoption Survey. Clin Exp Hypertens A 1986, 8:653-660.
6. Staessen J.A., Wang J., Bianchi G., Birkenhager W.H. Essential hypertension. Lancet 2003, 361:1629-1641.
7. Caulfield M., Munroe P., Pembroke J., et al. Genome-wide mapping of human loci for essential hypertension. Lancet 2003, 361:2118-2123.
8. Padmanabhan S., Delles C., Dominiczak A.F. Genetic factors in hypertension. Arch Med Sci 2009, 5(2A):S212-S219.
9. Jeemon P., Pettigrew K., Sainsbury C., Prabhakaran D., Padmanabhan S. Implications of discoveries from genome-wide association studies in current cardiovascular practice. World J Cardiol 2011, 3:230-247.
10. Blackwelder W.C., Elston R.C. A comparison of sib-pair linkage tests for disease susceptibility loci. Genet Epidemiol 1985, 2:85-97.
11. Binder A. A review of the genetics of essential hypertension. Curr Opin Cardiol 2007, 22:176-184.
12. Koivukoski L., Fisher S.A., Kanninen T., et al. Meta-analysis of genome-wide scans for hypertension and blood pressure in Caucasians shows evidence of susceptibility regions on chromosomes 2 and 3. Hum Mol Genet 2004, 13:2325-2332.
13. Padmanabhan S., Wallace C., Munroe P.B., et al. Chromosome 2p shows significant linkage to antihypertensive response in the British Genetics of Hypertension Study. Hypertension 2006, 47:603-608.
14. Barkley R.A., Chakravarti A., Cooper R.S., et al. Positional identification of hypertension susceptibility genes on chromosome 2. Hypertension 2004, 43:477-482.
15. Matsuzaki H., Dong S., Loi H., et al. Genotyping over 100,000 SNPs on a pair of oligonucleotide arrays. Nat Methods 2004, 1:109-111.
16. Gunderson K.L., Steemers F.J., Lee G., Mendoza L.G., Chee M.S. A genome-wide scalable SNP genotyping assay using microarray technology. Nat Genet 2005, 37:549-554.
17. Levy D., Larson M.G., Benjamin E.J., et al. Framingham Heart Study 100K Project: genome-wide associations for blood pressure and arterial stiffness. BMC Med Genet 2007, 8(suppl 1):S3.
18. Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature 2007, 447:661-678. Wellcome Trust Case Control Consortium.
19. Newton-Cheh C., Johnson T., Gateva V., et al. Genome-wide association study identifies eight loci associated with blood pressure. Nat Genet 2009, 41:666-676.
20. Levy D., Ehret G.B., Rice K., et al. Genome-wide association study of blood pressure and hypertension. Nat Genet 2009, 41:677-687.
21. Wain L.V., Verwoert G.C., O'Reilly P.F., et al. Genome-wide association study identifies six new loci influencing pulse pressure and mean arterial pressure. Nat Genet 2011, 43:1005-1011.
22. Cho Y.S., Go M.J., Kim Y.J., et al. A large-scale genome-wide association study of Asian populations uncovers genetic factors influencing eight quantitative traits. Nat Genet 2009, 41:527-534.
23. Ehret G.B., Munroe P.B., Rice K.M., et al. Genetic variants in novel pathways influence blood pressure and cardiovascular disease risk. Nature 2011, 478:103-109.
24. Padmanabhan S., Melander O., Johnson T., et al. Genome-wide association study of blood pressure extremes identifies variant near UMOD associated with hypertension. PLoS Genet 2010, 6:e1001177.
25. Hastie C.E., Padmanabhan S., Dominiczak A.F. Genome-wide association studies of hypertension: light at the end of the tunnel. Int J Hypertens 2010, 2010:509581.
26. Lee W.K., Padmanabhan S., Dominiczak A.F. Genetics of hypertension: from experimental models to clinical applications. J Hum Hypertens 2000, 14:631-647.
27. Delles C., McBride M.W., Graham D., Padmanabhan S., Dominiczak A.F. Genetics of hypertension: from experimental animals to humans. Biochim Biophys Acta 2010, 1802:1299-1308.
28. Jeunemaitre X. Genetics of the human renin angiotensin system. J Mol Med 2008, 86:637-641.
29. Rudnicki M., Mayer G. Significance of genetic polymorphisms of the renin-angiotensin-aldosterone system in cardiovascular and renal disease. Pharmacogenomics 2009, 10:463-476.
30. Pereira T.V., Nunes A.C., Rudnicki M., et al. Meta-analysis of the association of 4 angiotensinogen polymorphisms with essential hypertension: a role beyond M235T?. Hypertension 2008, 51:778-783.
31. Zhu H., Wang X., Lu Y., et al. Update on G-protein polymorphisms in hypertension. Curr Hypertens Rep 2006, 8:23-29.
32. Bianchi G., Ferrari P., Staessen J.A. Adducin polymorphism: detection and impact on hypertension and related disorders. Hypertension 2005, 45:331-340.
33. Delles C., Moreno M.U., Padmanabhan S., et al. Functional genomics of the oxidative stress pathway. Curr Hypertens Rev 2009, 3:156-165.
34. San Jose G., Fortuno A., Beloqui O., Diez J., Zalba G. NADPH oxidase CYBA polymorphisms, oxidative stress and cardiovascular diseases. Clin Sci (Lond) 2008, 114:173-182.
35. Johnson T., Gaunt T.R., Newhouse S.J., et al. Blood pressure loci identified with a gene-centric array. Am J Hum Genet 2011, 89:688-700.
36. Padmanabhan S., Menni C., Lee W.K., et al. The effects of sex and method of blood pressure measurement on genetic associations with blood pressure in the PAMELA study. J Hypertens 2010, 28:465-477.
37. Tomaszewski M., Debiec R., Braund P.S., et al. Genetic architecture of ambulatory blood pressure in the general population: insights from cardiovascular gene-centric array. Hypertension 2010, 56:1069-1076.
38. Sober S., Org E., Kepp K., et al. Targeting 160 candidate genes for blood pressure regulation with a genome-wide genotyping array. PLoS One 2009, 4:e6034.
39. Ji W., Foo J.N., O'Roak B.J., et al. Rare independent mutations in renal salt handling genes contribute to blood pressure variation. Nat Genet 2008, 40:592-599.
40. Sanders S. Whole-exome sequencing: a powerful technique for identifying novel genes of complex disorders. Clin Genet 2011, 79:132-133.
41. Harrap S.B. Where are all the blood-pressure genes?. Lancet 2003, 361:2149-2151.
42. Kurtz T.W. Genome-wide association studies will unlock the genetic basis of hypertension.: con side of the argument. Hypertension 2010, 56:1021-1025.
43. Dominiczak A.F., Munroe P.B. Genome-wide association studies will unlock the genetic basis of hypertension: pro side of the argument. Hypertension 2010, 56:1017-1020.
44. Bell J. The new genetics in clinical practice. BMJ 1998, 316:618-620.
45. Sookoian S., Gianotti T.F., Gonzalez C.D., Pirola C.J. Association of the C-344T aldosterone synthase gene variant with essential hypertension: a meta-analysis. J Hypertens 2007, 25:5-13.
46. Vyletal P., Bleyer A.J., Kmoch S. Uromodulin biology and pathophysiology-an update. Kidney Blood Press Res 2010, 33:456-475.
47. Prajczer S., Heidenreich U., Pfaller W., et al. Evidence for a role of uromodulin in chronic kidney disease progression. Nephrol Dial Transplant 2010, 25:1896-1903.
48. Eddy A.A. Scraping fibrosis: UMODulating renal fibrosis. Nat Med 2011, 17:553-555.
49. Good D.M., Zurbig P., Argiles A., et al. Naturally occurring human urinary peptides for use in diagnosis of chronic kidney disease. Mol Cell Proteomics 2010, 9:2424-2437.
50. Kottgen A., Glazer N.L., Dehghan A., et al. Multiple loci associated with indices of renal function and chronic kidney disease. Nat Genet 2009, 41:712-717.
51. Liu C.T., Garnaas M.K., Tin A., et al. Genetic association for renal traits among participants of African ancestry reveals new loci for renal function. PLoS Genet 2011, 7:e1002264.
52. Gudbjartsson D.F., Holm H., Indridason O.S., et al. Association of variants at UMOD with chronic kidney disease and kidney stones-role of age and comorbid diseases. PLoS Genet 2010, 6:e1001039.
53. Boger C.A., Gorski M., Li M., et al. Association of eGFR-related loci identified by GWAS with incident CKD and ESRD. PLoS Genet 2011, 7:e1002292.
54. Bachmann S., Mutig K., Bates J., et al. Renal effects of Tamm-Horsfall protein (uromodulin) deficiency in mice. Am J Physiol Renal Physiol 2005, 288:F559-F567.
55. Kottgen A., Hwang S.J., Larson M.G., et al. Uromodulin levels associate with a common UMOD variant and risk for incident CKD. J Am Soc Nephrol 2010, 21:337-344.
56. O'Seaghdha C.M., Perkovic V., Lam T.H., et al. Blood pressure is a major risk factor for renal death: an analysis of 560 352 participants from the Asia-Pacific region. Hypertension 2009, 54:509-515.
57. Goldstein J.L., Brown M.S. Familial hypercholesterolemia: identification of a defect in the regulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase activity associated with overproduction of cholesterol. Proc Natl Acad Sci U S A 1973, 70:2804-2808.
58. Law M.R., Wald N.J., Rudnicka A.R. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. BMJ 2003, 326:1423.
59. Kathiresan S., Melander O., Guiducci C., et al. Six new loci associated with blood low-density lipoprotein cholesterol, high-density lipoprotein cholesterol or triglycerides in humans. Nat Genet 2008, 40:189-197.
60. Keyhani S., Diener-West M., Powe N. Are development times for pharmaceuticals increasing or decreasing?. Health Aff (Millwood) 2006, 25:461-468.
61. Mega J.L., Hochholzer W., Frelinger A.L., et al. Dosing clopidogrel based on CYP2C19 genotype and the effect on platelet reactivity in patients with stable cardiovascular disease. JAMA 2011, 306:2221-2228.
62. Link E., Parish S., Armitage J., et al. SLCO1B1 variants and statin-induced myopathy-a genomewide study. N Engl J Med 2008, 359:789-799.
63. Maggo S.D., Kennedy M.A., Clark D.W. Clinical implications of pharmacogenetic variation on the effects of statins. Drug Saf 2011, 34:1-19.
64. Schwartz G.L., Turner S.T. Pharmacogenetics of antihypertensive drug responses. Am J Pharmacogenomics 2004, 4:151-160.
65. Turner S.T., Bailey K.R., Fridley B.L., et al. Genomic association analysis suggests chromosome 12 locus influencing antihypertensive response to thiazide diuretic. Hypertension 2008, 52:359-365.
66. Hlatky M.A., Greenland P., Arnett D.K., et al. Criteria for evaluation of novel markers of cardiovascular risk: a scientific statement from the American Heart Association. Circulation 2009, 119:2408-2416.
67. Chakravarti A., Little P. Nature, nurture and human disease. Nature 2003, 421:412-414.
68. Manolio T.A., Bailey-Wilson J.E., Collins F.S. Genes, environment and the value of prospective cohort studies. Nat Rev Genet 2006, 7:812-820.
69. Torffvit O., Melander O., Hulten U.L. Urinary excretion rate of Tamm-Horsfall protein is related to salt intake in humans. Nephron Physiol 2004, 97:31-36.
70. Ying W.Z., Sanders P.W. Dietary salt regulates expression of Tamm-Horsfall glycoprotein in rats. Kidney Int 1998, 54:1150-1156.
71. Seda O., Tremblay J., Gaudet D., et al. Systematic, genome-wide, sex-specific linkage of cardiovascular traits in French Canadians. Hypertension 2008, 51:1156-1162.
72. Pausova Z., Gaudet D., Gossard F., et al. Genome-wide scan for linkage to obesity-associated hypertension in French Canadians. Hypertension 2005, 46:1280-1285.
73. Morris B.J. Dissecting hypertension by obesity identifies a locus at 1p36. Hypertension 2005, 46:1256-1258.
74. Craddock N., Hurles M.E., Cardin N., et al. Genome-wide association study of CNVs in 16,000 cases of eight common diseases and 3,000 shared controls. Nature 2010, 464:713-720.
75. Kathiresan S., Voight B.F., Purcell S., et al. Genome-wide association of early-onset myocardial infarction with single nucleotide polymorphisms and copy number variants. Nat Genet 2009, 41:334-341.
76. Dauber A., Yu Y., Turchin M.C., et al. Genome-wide association of copy-number variation reveals an association between short stature and the presence of low-frequency genomic deletions. Am J Hum Genet 2011, 89:751-759.
77. Elia J., Glessner J.T., Wang K., et al. Genome-wide copy number variation study associates metabotropic glutamate receptor gene networks with attention deficit hyperactivity disorder. Nat Genet 2011, 44:78-84.
78. Hai R., Pei Y.F., Shen H., et al. Genome-wide association study of copy number variation identified gremlin1 as a candidate gene for lean body mass. J Hum Genet 2012, 57:33-37.